Phase 2 Trial Results Suggest Baricitinib Is Effective for SLE

At Week 24, researchers found 67% of patients receiving 4 mg baricitinib achieved resolution of SLEDAI-2K arthritis or rash. The safety profile of baricitinib in patients with active SLE receiving standard of care treatment was consistent with previously published findings. The 4 mg treatment group experienced a single episode of deep-vein thrombosis. Baricitinib treatment also resulted in modest dose-associated decreases in hemoglobin neutrophil and triglyceride concentrations, as well as increases in platelet counts, concentrations of creatine phosphokinase, HDL cholesterol and total cholesterol.

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

Reference

Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018 Jul 21;392(10143):222–231. doi: 10.1016/S0140-6736(18)31363-1.

A decade after JAK inhibitors were approved, this EULAR 2022 session looks at whether the drugs have lived up to expectations.

Dr. Pisetsky’s picks for the top research in lupus presented at ACR Convergence 2021.

In a recent study, baricitinib proved more effective than adalimumab in treating adults with RA through 52 weeks…

Brodalumab Approved for Plaque Psoriasis The U.S. Food and Drug Administration has approved brodalumab, a monoclonal antibody that targets interleukin 17 (IL‑17).1,2 Brodalumab (Siliq) was approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to respond to, or have lost response to, other…

JAK Inhibitors: Are All Promises Fulfilled?

Top 12: Research in Systemic Lupus Erythematosus at a Glance

Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA

Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA

Related Articles